Using circulating tumor cells to inform on prostate cancer biology and clinical utility

Li, Jing; Gregory, Simon G.; García-Blanco, Mariano A.; Armstrong, Andrew J.

doi:10.3109/10408363.2015.1023430

Cited by 20 publications

(15 citation statements)

References 160 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The enrichment of CTCs is achieved by using immunomagnetic antibodies against EpCAM. [4] [5] [32] [33] There are no FDA-approved assays to detect DTCs, which make it difficult to standardize detection of PCa DTCs as the field attempts to determine the significance of disseminated cells at the time of primary therapy. [34] CTC systems are being adapted to isolate and detect DTCs in the BM.…”

Section: Detection Of Circulating and Disseminated Tumor Cellsmentioning

confidence: 99%

Disseminated tumor cells and dormancy in prostate cancer metastasis

Toom

Verdone²,

Pienta

2016

Current Opinion in Biotechnology

View full text Add to dashboard Cite

It has been reported that disseminated tumor cells (DTCs) can be found in the majority of prostate cancer (PCa) patients, even at the time of primary treatment with no clinical evidence of metastatic disease. This suggests that these cells escaped the primary tumor early in the disease and exist in a dormant state in distant organs until they develop in some patients as overt metastases. Understanding the mechanisms by which cancer cells exit the primary tumor, survive the circulation, settle in a distant organ, and exist in a quiescent state is critical to understanding tumorigenesis, developing new prognostic assays, and designing new therapeutic modalities to prevent and treat clinical metastases.

show abstract

Section: Detection Of Circulating and Disseminated Tumor Cellsmentioning

confidence: 99%

Disseminated tumor cells and dormancy in prostate cancer metastasis

Toom

Verdone²,

Pienta

2016

Current Opinion in Biotechnology

View full text Add to dashboard Cite

show abstract

“…The CTC-Chip [25,243], and the herringbone chip [244,245] have been proven effective to isolate CTCs with both high CTC purity (50-62%) [25,245] and high recovery rate (90-95%) [244,245]. There are several microfluidic devices designed to use positive selection strategy for proof-of-concept purpose [34,57,59,124,184,210, and for specific cancer in clinical trials, (e.g., breast [270,271], pancreas [272,273], ovarian [274], prostate [275], esophageal cancer [270], gastric [271], colorectal cancer [276], cancer of unknown primary [277]) and for mutational analysis [278]. Moreover, combined preparation using positive, negative, or label-free selection methods with microfluidic devices for better performance is also feasible and have been reported [93].…”

Section: Microfluidic-based Methods For the High Purity Ctc Isolationmentioning

confidence: 99%

The Selection Strategy for Circulating Tumor Cells (CTCs) Isolation and Enumeration: Technical Features, Methods, and Clinical Applications

Hsieh¹,

Wu²

2016

Tumor Metastasis

View full text Add to dashboard Cite

The key aim of the proposed chapter is to provide readers a brief description for the most important parts of the field of circulating tumor cells (CTCs): the core techniques, including negative and positive selection-based CTC isolation, and the differences between them. Most importantly, we will also review the clinical applications and important findings in clinical trials. The evidence-based review will not only help clinicians use CTCs to predict recurrence and foresee the disease-related outcomes but also to inspire the researchers in this field to conduct further investigations.

show abstract

“…To date, the only prognostic PCa biomarker approved by the US Food and Drug Administration is circulation tumor cell counts (CTCs) (4). One may envision that genomic or proteomic profiling of relapsing CTCs can provide novel prognostic or predictive biomarkers to aid in the development of whole-organ and body imaging and therapy of CRPC patients.…”

Section: Prostate Cancer (Pca)mentioning

confidence: 99%

Targeting Prostate Cancer Stem Cells with Alpha-Particle Therapy

Ceder

Elgqvist

2017

Front. Oncol.

View full text Add to dashboard Cite

Modern molecular and radiopharmaceutical development has brought the promise of tumor-selective delivery of antibody–drug conjugates to tumor cells for the diagnosis and treatment of primary and disseminated tumor disease. The classical mode of discourse regarding targeted therapy has been that the antigen targeted must be highly and homogenously expressed in the tumor cell population, and at the same time exhibit low expression in healthy tissue. However, there is increasing evidence that the reason cancer patients are not cured by current protocols is that there exist subpopulations of cancer cells that are resistant to conventional therapy including radioresistance and that these cells express other target antigens than the bulk of the tumor cells. These types of cells are often referred to as cancer stem cells (CSCs). The CSCs are tumorigenic and have the ability to give rise to all types of cells found in a cancerous disease through the processes of self-renewal and differentiation. If the CSCs are not eradicated, the cancer is likely to recur after therapy. Due to some of the characteristics of alpha particles, such as short path length and high density of energy depositions per distance traveled in tissue, they are especially well suited for use in targeted therapies against microscopic cancerous disease. The characteristics of alpha particles further make it possible to minimize the irradiation of non-targeted surrounding healthy tissue, but most importantly, make it possible to deliver high-absorbed doses locally and therefore eradicating small tumor cell clusters on the submillimeter level, or even single tumor cells. When alpha particles pass through a cell, they cause severe damage to the cell membrane, cytoplasm, and nucleus, including double-strand breaks of DNA that are very difficult to repair for the cell. This means that very few hits to a cell by alpha particles are needed in order to cause cell death, enabling killing of cells, such as CSCs, exhibiting cellular resistance mechanisms to conventional therapy. This paper presents and evaluates the possibility of using alpha-particle emitting radionuclides in the treatment of prostate cancer (PCa) and discusses the parameters that have to be considered as well as pros and cons of targeted alpha-particle therapy in the treatment of PCa. By targeting and eradicating the CSCs responsible of tumor recurrence in patients who no longer respond to conventional therapies, including androgen deprivation and castration, it may be possible to cure the disease, or prolong survival significantly.

show abstract

Using circulating tumor cells to inform on prostate cancer biology and clinical utility

Cited by 20 publications

References 160 publications

Disseminated tumor cells and dormancy in prostate cancer metastasis

Disseminated tumor cells and dormancy in prostate cancer metastasis

The Selection Strategy for Circulating Tumor Cells (CTCs) Isolation and Enumeration: Technical Features, Methods, and Clinical Applications

Targeting Prostate Cancer Stem Cells with Alpha-Particle Therapy

Contact Info

Product

Resources

About